Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this randomised four-period cross-over Phase I study is to assess bioavailability, bioequivalence and tolerability of IHL-42X compared to the reference drugs in healthy volunteers.

Volunteers will be enrolled and randomised to one of four treatment groups. Each group is to receive all four treatments in a twenty eight day cross-over study, with each treatment period running for seven days.

The four treatment groups are described below; A = dronabinol 5 mg, fasted; B = acetazolamide 250 mg, fasted; C = IHL-42X (5 mg dronabinol, 250 mg acetazolamide), fasted; D = IHL-42X (5 mg dronabinol, 250 mg acetazolamide), fed. Each treatment group will enrol at least 29 participants each, for a total of at least 116 participants.

Bioavailability and bioequivalence will assess and compare all four of the seven day treatments.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Incannex Healthcare Ltd
• Treatments: Acetazolamide; Dronabinol

Criteria

Inclusion Criteria:

• Healthy volunteers will be enrolled in the study if they satisfy all the following criteria:

1. Ages ≥18 to ≤65 at the time of screening

2. BMI ≥18.0 to ≤32.0

3. Physically well, in the opinion of the investigator, with no clinically significant psychiatric, cardiac, hepatic, renal, endocrine, gastrointestinal, bleeding, thyroid, cholesterol, or hypertension disorders

4. If male, willing to use an approved method of contraception from 30 days prior to dosing, throughout the study, and 90 days after last dose.

Options include:

Surgically sterile (vasectomy at least 6 months prior to dosing) Condom + partner with IUD device (in place 3 months prior to dosing through to 90 days after last dose) Condom + partner with diaphragm for at least 30 days prior to dosing through to 90 days after last dose Condom + partner using hormonal contraception for at least 3 months prior to dosing + condom for at least 30 days prior to dosing through to 90 days after last dose OR Contraception not required Sexual partner is surgically sterile. Partner is of non-childbearing potential Same sex relationship Abstinence

5. If female of non-childbearing potential, must be postmenopausal with established serum FSH levels >30IU/L (determined during screening or have undergone one of the following sterilization procedures at least 6 months prior to Visit Day 1;

1. Bilateral tubal ligation

2. Hysterectomy

3. Hysterectomy with unilateral or bilateral oophorectomy

4. Bilateral oophorectomy If females of childbearing potential must not be currently pregnant, lactating, or planning to be pregnant and are willing to use an approved method of contraception from 30 days prior to dosing, throughout the study, and 30 days after last dose.

Options include:

Condom + IUD device (in place 3 months prior to dosing + 30 days after last dose) Condom + Diaphragm for at least 30 days prior to dosing + 30 days after last dose Condom + Hormonal contraception for at least 3 months prior to dosing + condom for at least 30 days prior to dosing + 30 days after last dose OR Contraception not required Partner has had a vasectomy at least 6 months prior to first dose Of non-childbearing potential (postmenopausal or surgically sterile by any method for at least 3 months prior to check-in) Abstinence Same sex relationship

6. Voluntarily consent to participate in the study and complete all study required tasks, as instructed by the protocol, including the completion of questionnaires.

Exclusion Criteria:

• Healthy volunteers will be excluded from the study if there is evidence of any of the following at screening, or prior to dosing at the timepoints in the Schedule of Events.

1. History of cardiac disease or arrythmias

2. History of significant psychiatric illness (defined as hospitalisation or history of pharmacological prescription for psychiatric conditions), suicidal ideation, or suicidal attempts

3. Current use of illicit drugs or as defined by a positive urine drug test at screening or baseline

4. History of alcohol abuse or excessive alcohol intake according to the Australian guidelines (more than 10 standard drinks per week/4 standard drinks per day on average) or alcohol consumption (by self-declaration) defined as > 21 alcohol units per week (where 1 unit = 284 mL of beer, 25 mL of 40% spirit, or a 125 mL glass of wine).

5. Any cannabis use within 30 days of screening

6. Known hypersensitivity and/or intolerance to any cannabis products with previous use

7. Known hypersensitivity and/or intolerance to sesame oil (dronabinol is formulated in sesame oil)

8. Known hypersensitivity and/or intolerance to acetazolamide

9. Has taken any vitamins, herbal remedies, supplements or cannabidiol products within 7 days of each check-in

10. GAD-7 score of ≥15, MDI score ≥31 OR 3 core symptoms and 5 accompanying symptoms, C-SSRS score ≥4 OR reported suicidal behaviour within the past 3 months

11. Any dietary requirements incompatible with study breakfast; must be able to eat high-fat, high-calorie diet (including meat, dairy products) (As described in FDA guidance for BA and BE studies (Appendix 6))

12. Hepatic or renal impairment or disease, as defined as AST/ALT >1.5 x ULN, eGFR <60 at screening and check-in.

13. History of gastrointestinal disorders or previous surgeries which may impact absorption, distribution, metabolism and/or excretion of the IP (such as cholecystitis, cholecystectomy)

14. Female participants who are pregnant, lactating or planning to become pregnant

15. Inability to adhere to the protocol and study restrictions during the study period

16. Participation in another clinical trial of an investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to first study drug administration.

17. Any other reason in the opinion of the investigator